EBV-miR-BHRF1-1 Targets p53 Gene: Potential Role in Epstein-Barr Virus Associated Chronic Lymphocytic Leukemia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to investigate the prognostic impact of Epstein-Barr virus (EBV)–microRNA (miRNA, miR)-BHRF1-1 with chronic lymphocytic leukemia (CLL) as well as role of EBV-miR-BHRF1-1 in p53 gene. Materials and Methods Quantitative reverse transcription–polymerase chain reaction and western blotting were used to quantify EBV-miR-BHRF1-1 and p53 expression in cultured CLL. Results p53 aberration was associated with the higher expression level of EBV-miR-BHRF1-1 (p < 0.001) which was also an independent prognostic marker for overall survival (p=0.028; hazard ratio, 5.335; 95% confidence interval, 1.193 to 23.846) in 97 newly-diagnosed CLL patients after adjusted with International Prognostic Index for patients with CLL. We identified EBV-miR-BHRF1-1 as a viral miRNA regulator of p53. EBV-miR-BHRF1-1 repressed luciferase reporter activity by specific interaction with the seed region within the p53 3- untranslated region. Discordance of p53 messenger RNA and protein expression was associated with high EBV-miR-BHRF1-1 levels in CLL patients and cell lines. EBV-miR-BHRF1- 1 inhibition upregulated p53 protein expression, induced cell cycle arrest and apoptosis and decreased cell proliferation in cell lines. EBV-miR-BHRF1-1 mimics downregulated p53 protein expression, decreased cell cycle arrest and apoptosis, and induced cell proliferation in cell lines. Conclusion This study supported the role of EBV-miR-BHRF1-1 in p53 regulation in vitro. Our results support the potential of EBV-miR-BHRF1-1 as a therapeutic target in EBV-associated CLL with p53 gene aberration.
Abstract
Purpose The purpose of this study was to investigate the prognostic impact of Epstein-Barr virus (EBV)–microRNA (miRNA, miR)-BHRF1-1 with chronic lymphocytic leukemia (CLL) as well as role of EBV-miR-BHRF1-1 in p53 gene. Materials and Methods Quantitative reverse transcription–polymerase chain reaction and western blotting were used to quantify EBV-miR-BHRF1-1 and p53 expression in cultured CLL. Results p53 aberration was associated with the higher expression level of EBV-miR-BHRF1-1 (p < 0.001) which was also an independent prognostic marker for overall survival (p=0.028; hazard ratio, 5.335; 95% confidence interval, 1.193 to 23.846) in 97 newly-diagnosed CLL patients after adjusted with International Prognostic Index for patients with CLL. We identified EBV-miR-BHRF1-1 as a viral miRNA regulator of p53. EBV-miR-BHRF1-1 repressed luciferase reporter activity by specific interaction with the seed region within the p53 3- untranslated region. Discordance of p53 messenger RNA and protein expression was associated with high EBV-miR-BHRF1-1 levels in CLL patients and cell lines. EBV-miR-BHRF1- 1 inhibition upregulated p53 protein expression, induced cell cycle arrest and apoptosis and decreased cell proliferation in cell lines. EBV-miR-BHRF1-1 mimics downregulated p53 protein expression, decreased cell cycle arrest and apoptosis, and induced cell proliferation in cell lines. Conclusion This study supported the role of EBV-miR-BHRF1-1 in p53 regulation in vitro. Our results support the potential of EBV-miR-BHRF1-1 as a therapeutic target in EBV-associated CLL with p53 gene aberration.
참고문헌 (16)
- Pfeffer S, "Identification of virus-encoded microRNAs", Science, 304, pp.734~736 (2004)
- Qiu J, "A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia", PLoS Pathog, 7, pp.e1002193~ (2011)
- Imig J, "microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma", Nucleic Acids Res, 39, pp.1880~1893 (2011)
- Barth S, "EBV-encoded miRNAs", Biochim Biophys Acta, 1809, pp.631~640 (2011)
- Navari M, "Pathobiologic roles of Epstein-Barr virus-encoded microRNAs in human lymphomas", Int J Mol Sci, 19, pp.E1168~ (2018)
- Liang JH, "Prognostic impact of Epstein-Barr virus(EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia", Oncotarget, 7, pp.2135~2142 (2016)
- Visco C, "Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival", Oncotarget, 6, pp.18653~18663 (2015)
- Baliakas P, "Recurrent mutations refine prognosis in chronic lymphocytic leukemia", Leukemia, 29, pp.329~336 (2015)
- Roberts AW, "Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia", N Engl J Med, 374, pp.311~322 (2016)
- Burger JA, "Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia", Blood, 133, pp.1011~1019 (2019)
- Li Z, "EBV encoded miR-BHRF1-1 potentiates viral lytic replication by downregulating host p53 in nasopharyngeal carcinoma", Int J Biochem Cell Biol, 44, pp.275~279 (2012)
- Hallek M, "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996guidelines", Blood, 111, pp.5446~5456 (2008)
- International CLL-IPI Working Group, "An international prognostic index for patients with chronic lymphocytic leukaemia(CLL-IPI) : a meta-analysis of individual patient data", Lancet Oncol, 17, pp.779~790 (2016)
- Tarrand JJ, "Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia", Cancer, 116, pp.880~887 (2010)
- Renouf B, "Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus(EBV)-positive and EBVnegative Burkitt's lymphoma cells", Leukemia, 23, pp.1557~1563 (2009)
- AlQarni S, "Lymphomas driven by Epstein-Barr virus nuclear antigen-1(EBNA1)are dependant upon Mdm2", Oncogene, 37, pp.3998~4012 (2018)